Cookie Consent by PrivacyPolicies.com

Publicaciones científicas

14 Publicaciones científicas disponibles

  • Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma

    18 de julio de 2019 | Revista: The Lancet. Haematology

    Mateos MV (1), Blacklock H (2), Schjesvold F (3), Oriol A (4), Simpson D (5), George A (6), Goldschmidt H (7), Larocca A (8), Chanan-Khan A (9), Sherbenou D (10), Avivi I (11), Benyamini N (12), Iida S (13), Matsumoto M (14), Suzuki K (15), Ribrag V (16), Usmani SZ (17), Jagannath S (18), Ocio EM (19), Rodriguez-Otero P (20), San Miguel J (20), Kher U (21), Farooqui M (21), Liao J (21), Marinello P (21), Lonial S (22); KEYNOTE-183 Investigators.

    (1) Complejo Asistencial Universitario de Salamanca/IBSAL, Salamanca, Spain.
    (2) Middlemore Hospital, Auckland, New Zealand.
    (3) Oslo Myeloma Center, Oslo University Hospital and KG Jebsen Center for B-Cell Malignancies, University of Oslo, Oslo, Norway.
    (4) Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Triasi Pujol, Barcelona, Spain.
    (5) North Shore Hospital, Auckland, New Zealand.
    (6) Wellington Blood and Cancer Center, Wellington, New Zealand.
    (7) University Hospital Heidelberg and National Center of Tumor Diseases in Heidelberg, Heidelberg, Germany.
    (8) Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.
    (9) Mayo Clinic, Jacksonville, FL, USA.
    (10) University of Colorado Cancer Center, Denver, CO, USA.
    (11) Sourasky Medical Center, Haifa, Israel.
    (12) Rambam Health Care Campus, HaAliya HaShniya, Israel.
    (13) Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Japan.
    (14) National Hospital Organization, Shibukawa Medical Center, Shibukawa, Gunma, Japan.
    (15) Japanese Red Cross, Tokyo, Japan.
    (16) Institut Gustave Roussy, Villejuif, France.
    (17) Levine Cancer Institute/Atrium Health, Charlotte, NC, USA.
    (18) The Mount Sinai Medical Hospital, New York, NY, USA.
    (19) Hospital Universitario Marqués de Valdecilla (IDIVAL), Universidad de Cantabria, Santander, Spain.
    (20) Clinica Universidad de Navarra, CIMA, IDISNA, CIBERONC, Pamplona, Spain.
    (21) Merck & Co, Kenilworth, NJ, USA.
    (22) Winship Cancer Institute, Emory University, Atlanta, GA, USA.


  • The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma

    15 de mayo de 2019 | Revista: Clínical Cancer Research

    Moreno L (1), Perez C (1), Zabaleta A (1), Manrique I (1), Alignani D (1), Ajona D (1,2,3), Blanco L (1), Lasa M (1), Maiso P (1), Rodriguez I (1), Garate S (1), Jelinek T (1), Segura V (1), Moreno C (1), Merino J (1), Rodriguez-Otero P (1), Panizo C (1), Prosper F (1), San-Miguel JF (1), Paiva B (4).

    (1) Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369 and CB16/12/00489, Pamplona, Spain.
    (2) Solid Tumors Program, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00443, Pamplona, Spain.
    (3) Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain.
    (4) Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369 and CB16/12/00489, Pamplona, Spain.


  • Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose

    12 de abril de 2018 | Revista: Haematologica

    Martinez-Calle N (1), Rodriguez-Otero P (2), Villar S (2), Mejías L (2), Melero I (3), Prosper F (2), Marinello P (4), Paiva B (5), Idoate M (2), San-Miguel J (2).

    (1) Clínica Universidad de Navarra, Pamplona, Spain.
    (2) Clínica Universidad de Navarra, Pamplona, Spain.
    (3) Centro de Investigaciín Médica Aplicada (CIMA), Pamplona, Spain.
    (4) Merck Sharp and Dohme Laboratories.Inc., Kenilworth, NJ, USA.
    (5) Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain.


  • Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role

    23 de febrero de 2018 | Revista: Leukemia

    Rodríguez-Otero P (1), Mateos MV (2), Martínez-López J (3), Martín-Calvo N (4), Hernández MT (5), Ocio EM (2), Rosiñol L (6), Martínez R (7), Teruel AI (8), Gutiérrez NC (2), Bargay J (9), Bengoechea E (10), González Y (11), de Oteyza JP (12), Gironella M (13), Encinas C (14), Martín J (15), Cabrera C (16), Palomera L (17), de Arriba F (18), Cedena MT (3), Paiva B (1), Puig N (2), Oriol A (19), Bladé J (6), Lahuerta JJ (4), San Miguel JF (20).

    (1) Clínica Universidad de Navarra, CIMA, IDISNA, CIBERONC, Pamplona, Spain.
    (2) Complejo Asistencial Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Salamanca, Spain.
    (3) Hospital Universitario 12 de Octubre, Instituto de Investigación 12 de Octubre, CIBERONC, Madrid, Spain.
    (4) Preventive Medicine and Public Health Department, University of Navarra, Pamplona, Spain.
    (5) Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain.
    (6) Hospital Clinic I Provincial, Institu d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
    (7) Hospital Clínico San Carlos, Madrid, Spain.
    (8) Hospital Clínico de Valencia, Valencia, Spain.
    (9) Hospital Son Llatzer, Palma de Mallorca, Spain.
    (10) Hospital de Donostia, San Sebastian, Spain.
    (11) Institut d'Oncologia Dr. Josep Trueta, Girona, Spain.
    (12) Hospital de Madrid Sanchinarro, Universidad CEU San Pablo, Madrid, Spain.
    (13) Hospital Vall d'Hebron, Barcelona, Spain.
    (14) Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain.
    (15) Hospital General Virgen del Rocío, Sevilla, Spain.
    (16) Hospital San Pedro de Alcántara, Cáceres, Spain.
    (17) Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.
    (18) Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain.
    (19) Insitut Català d'Oncologia, Institut Josep Carreras, Hospital German Trias i Pujol, Badalona, Barcelona, Spain.
    (20) Clínica Universidad de Navarra, CIMA, IDISNA, CIBERONC, Pamplona, Spain.

No hay más publicaciones científicas

No hay más páginas para cargar